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Background: optimal empirical therapy of urinary tract infection requires accurate 
knowledge of local susceptibility patterns, which may vary with organism and patient 
characteristics. 
Methods: Among 9,798 consecutive, non-duplicate, community-source urine isolates from 
ambulatory patients ≥ 13 years old, from clinical laboratory and an academic medical 
center in curitiba, brazil (May 1st to December 1st, 2009), susceptibility data for ampicillin, 
nitrofurantoin, trimethoprim-sulfamethoxazole, gentamicin, fluoroquinolones, and 
ceftriaxone/cefotaxime were compared with organism and patient gender and age.
Results: the female-to-male ratio decreased with age, from 28.1 (among 20-29 year-olds) 
to 3.3 (among > 80 year-olds). overall, susceptibility prevalence varied widely by drug 
class, from unacceptably low levels (53.5% and 61.1%: ampicillin and trimethoprim-
sulfamethoxazole) to acceptable but suboptimal levels (81.2% to 91.7%: fluoroquinolones, 
ceftriaxone, nitrofurantoin, and gentamicin). E. coli isolates exhibited higher susceptibility 
rates than other isolates, from 3-4% higher (fluoroquinolones, gentamicin) to ≥ 30% 
(nitrofurantoin, ceftriaxone). Males exhibited lower susceptibility rates than females. Within 
each gender, susceptibility declined with increasing age. for females, only nitrofurantoin 
and gentamicin were suitable for empirical therapy (≥ 80% susceptibility) across all age 
cohorts; fluoroquinolones were suitable only through age 60, and ceftriaxone only through 
age 80. for males, only gentamicin yielded ≥ 80% susceptibility in any age cohort. 
Conclusion: few suitable empirical treatment options for community-source urinary tract 
infection were identified for women aged over 60 years or males of any age. Empirical 
therapy recommendations must consider the patient’s demographic characteristics. site-
specific, age and gender-stratified susceptibility surveillance involving all uropathogens 
is needed. 
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Introduction
symptomatic urinary tract infections (Utis) are among the 
commonest bacterial infections, resulting in millions of 
physician visits (mostly for acute cystitis) and hundreds 
of thousands of hospital admissions (mostly for acute 
pyelonephritis) annually in the United states.1 A variety of 
antimicrobial regimens, with varying efficacy, tolerability, and 
cost, can be used to treat Utis. therapy usually is selected 
before culture and susceptibility test results are available. 
thus, expert panels have developed evidence-based guidelines 
for empirical treatment of Uti, which requires the availability 
of high-quality data from surveillance studies regarding a 
major challenge in Uti therapy: antimicrobial resistance 
among uropathogens. 
the previous (1999) guidelines from the infectious Diseases 
society of America (iDsA) suggested fluoroquinolones (fQs) 
as an appropriate first-line therapy for uncomplicated acute 
cystitis or pyelonephritis in women if the local prevalence 
of resistance to trimethoprim-sulfamethoxazole (tMP-sMX) 
exceeds 10-20%.2 However, the emergence of fQ resistance 
among uropathogens may jeopardize the empirical use of 
this drug class. for example, a 2005-2006 study from London 
found 9.3% fQ resistance among E. coli urinary isolates, with a 
higher percentage among male and elderly patients.3 indeed, 
the susceptibility of community-source uropathogens to most 
commonly prescribed antimicrobials is decreasing globally.4-6 
Although the iDsA guidelines have been updated to address 
recent antimicrobial resistance trends,7 they still may not 
be applicable to developing countries, since few relevant 
resistance surveillance studies are available,8 and the existing 
ones include relatively few isolates and/or focus on hospital-
source uropathogens.9
because of the paucity of data regarding antimicrobial 
resistance among community-source uropathogens in brazilian 
cities, and increasingly frequent clinical failures (unpublished 
data, rocha JL and tuon ff), we assessed the susceptibility to 
relevant antimicrobials among 9,798 consecutive urine isolates 
from ambulatory patients in curitiba, brazil (2009). We then 
analyzed these data to identify suitable empirical therapy 
options for cystitis and more complicated presentations of 
Uti, both overall and specifically in relation to patient gender 
and age. 
Methods
Setting
the study site, curitiba, is the capital city of the brazilian state 
of Paraná. As the seventh largest city in brazil (1.8 million 
inhabitants), curitiba is the largest economic and cultural 
center in southern brazil and is home to four medical schools. 
the university hospital included in this study is a tertiary 
center with 700 beds. the private laboratory included in this 
study is the main private clinical laboratory in curitiba, having 
35 outpatient units distributed widely across the city, which 
send specimens for analysis to the central laboratory.
Samples and subjects
from May 1st to December 1st, 2009, all community-source 
urine isolates from patients presenting to outpatient clinics 
at the university hospital or recovered by the private laboratory 
were considered for possible study inclusion. isolates from 
urine cultures that yielded ≥ 105 cfU/mL underwent automated 
susceptibility testing (Vitek 2®) and were eligible for the study. 
Exclusion criteria included fungi, mixed cultures, multiple 
specimens from a given patient (in which case only the first 
sample per patient was used), age less than 13 years, and 
hospital inpatient status at the time of specimen collection.
susceptibility breakpoints were as specified by the 
clinical and Laboratory standard institute.10 intermediate 
susceptibility was analyzed as resistant. results are presented 
for 6 drugs (classes): ampicillin, nitrofurantoin, fQs, tMP-sMX, 
gentamicin, and extended-spectrum cephalosporins (Escs). 
ciprofloxacin and levofloxacin were analyzed as a single 
drug class (i.e., fQs), as were ceftriaxone and cefotaxime (i.e., 
Escs). susceptibility of Enterococcus spp. to gentamicin was 
assessed only with respect to high concentration testing (for 
synergy). intrinsic resistance to ampicillin was assumed for 
Klebsiella spp., Pseudomonas spp., and Enterobacter spp.; to Escs 
for Pseudomonas spp. and Enterococcus spp.; to tMP-sMX for 
Pseudomonas spp.; and to nitrofurantoin for Proteus spp and 
Pseudomonas spp. 
Data were analyzed using the free software r, version 
2.11 (the r foundation for statistical computing). Graphics 
were created using GraphPad Prisma 4.0 (GraphPad, La Jolla – 
UsA). clinical data included age and gender. Aggregate 
susceptibility data were reported as percentages with 95% 
confidence intervals. susceptibility values < 80% were regarded 
as indicating inadequate activity of the corresponding drug 
class for use as empirical therapy of Uti. continuous data were 
expressed as mean ± standard deviation (sD) or median with 
ranges. Dichotomous variables were compared using a χ2 test. 
the significance threshold was set at 0.05. 
Results
Study population 
between May 1st and December 1st, 2009, the 36 participating 
clinical laboratories in curitiba, brazil processed 67,650 
outpatient urine cultures, of which 12,567 (18.6%) were 
positive. of the positive cultures, 2,769 (22%) had ≥ 1 exclusion 
criteria, leaving 9,798 non-duplicate urine isolates and the 
corresponding source patients as the study population.
the 9,798 subjects (492 from outpatient clinics at the 
Hospital Universitário Evangélico de curitiba; 9,306 from 
the 35 participating frishmann-Aisengart laboratory units) 
comprised 8,700 females (88.8%) and 1,098 males (11.2%), 
for an overall female-to-male ratio of 7.9. on average, males 
were approximately 15 years older than females (mean age, 
61.8 ± 19.8 years [males], vs. 47.0 ± 20.5 years [females]: p < 0.001). 
A histogram with the number of cases according to age showed, 
for females, an early peak followed by a decline, compared 
with a steady gradual increase for males (fig. 1). Accordingly, 
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the female-to-male ratio was highest (at 28.1) in the second-
youngest cohort (age 21-30 years), then declined progressively 
with increasing age to a minimum of 3.3 in the age > 81 years 
cohort (fig. 1). thus, age significantly influenced the gender 
mix within the population.
Enterobacter spp. and Pseudomonas spp. (table 1). these 7 
organisms accounted for 91.8% of overall pathogens.
Susceptibility results
the susceptibility of the 9,798 study isolates to the 6 studied 
antimicrobial agents varied widely by drug class, ranging 
from unacceptably low values (for empirical therapy) of 
53.5% and 61.1% for ampicillin and tMP-sMX, respectively, to 
acceptable but still suboptimal values of 81.2% to 91.7% for fQs, 
Escs, nitrofurantoin, and gentamicin (table 2). notably, the 
corresponding values for the 6,480 E. coli isolates were 1% to 11% 
higher, in each drug class, than the total values, evidence that 
E. coli overestimated the susceptibility of the total uropathogen 
pool. Differences in susceptibility prevalence between E. coli 
and non-E. coli were substantially greater, ranging from 3-4% 
(for fQs and gentamicin) to ≥ 30% (for nitrofurantoin and 
Escs). three drug classes, i.e., nitrofurantoin, fQs, and Escs, 
exhibited ≥ 80% susceptibility for E. coli but < 80% susceptibility 
for non-E. coli (table 2), evidence that their acceptability for 
empirical therapy would depend on the likelihood that the 
urine organism was E. coli – which, as noted above, varied with 
gender, whereas the gender mix varied with age.
in view of these relationships, stratification of susceptibility 
results by gender and age revealed marked heterogeneity 
among subgroups (table 3). overall, females exhibited higher 
susceptibility values for all six drug classes than males. 
Moreover, within each gender, susceptibility to a given drug 
declined progressively with increasing age, in some instances 
after an initial increase (table 3).
consequently, for females, only nitrofurantoin and 
gentamicin provided adequate activity for empirical therapy 
(i.e., ≥ 80% susceptibility) across all age cohorts, whereas fQs 
provided adequate activity through age 60 but not thereafter, 
and Escs did so through age 80 but not thereafter. for males, 
the situation was even worse, with only gentamicin being 
suitable for empirical therapy in any of the age cohorts, and 
only in 5 of the 8 cohorts (table 3).
Fig. 1 - Age distribution by sex among 9,798 ambulatory 
patients with a positive urine culture (Curitiba, Brazil, 
2009). The female:male ratio (no. of females/no. of males) 
within each age cohort is expressed as a decimal value.
Organisms 
in turn, gender significantly influenced the distribution of 
urine organisms (table 1). Although E. coli, Enterococcus spp., 
and Klebsiella spp. were the three most prevalent pathogens 
among both females and males, E. coli was significantly more 
prevalent among females, whereas Enterococcus and Klebsiella 
were significantly more prevalent among males. Moreover, 
whereas for females the 4th and 5th most prevalent pathogens 
were Proteus spp. and S. saprophyticus, for males they were 
                 Number of isolates (column %)
Organism Total 
(n = 9,798)
Female 
(n = 8,700)
Male 
(n = 1,098)
p-valuea 
female vs. male
Escherichia coli 6,480 (66.1) 6,015 (69.1) 465 (42.3) < 0.001
Enterococcus spp. 793 (8.1) 626 (7.2) 167 (15.2) < 0.001
Klebsiella spp. 579 (5.9) 473 (5.4) 106 (9.7) < 0.001
Staphylococcus saprophyticus 381 (3.9) 372 (4.3) 9 (0.8) < 0.001
Proteus mirabilis 379 (3.9) 330 (3.8) 49 (4.5)
Enterobacter spp. 266 (2.7) 193 (2.2) 73 (6.6) < 0.001
Pseudomonas aeruginosa 117 (1.2) 48 (0.6) 69 (6.3) < 0.001
othersb 803 (8.2) 643 (7.4) 160 (14.6) < 0.001
ap-values (as calculated using the c2 test) are shown where p < 0.05; bother organisms, in descending order of overall prevalence (8.2% of total), 
included: coagulase-negative Staphylococcus (3.7%), Citrobacter spp. (1.2%), Staphylococcus aureus (1.1%).
Table 1 - Distribution of urinary organisms by patient sex among 9,798 community-source urine isolates from Curitiba, 
Brazil (2009)
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                  Susceptible, no. (column %)             p-valuea
Antimicrobialb Total 
(n = 9,798)
E. coli 
(n = 6,480)
Others 
(n = 3,318)
E. coli  
vs. total
E. coli  
vs. others
Ampicillin 5,242 (53.5) 3,622 (55.9) 1,620 (48.8) 0.003 < 0.001
nitrofurantoin 8,416 (85.9) 6,221 (96.0) 2,195 (66.2) < 0.001 < 0.001
tMP-sMXb 5,987 (61.1) 4,264 (65.8) 1,723 (51.9) < 0.001 < 0.001
fQsb 7,956 (81.2) 5,327 (82.2) 2,629 (79.2) < 0.001
Escsb 8,407 (85.8) 6,273 (96.8) 2,134 (64.3) < 0.001 < 0.001
Gentamicin 8,985 (91.7) 6,033 (93.1) 2,952 (89.0) 0.001 < 0.001
ap-values (by fishers exact test) are shown where p < 0.05; btMP-sMX, trimethoprim-sulfamethoxazole; fQs, fluoroquinolones (ciprofloxacin 
and levofloxacin); Escs, extended-spectrum cephalosoporins (ceftriaxone and cefotaxime).
Subjects                           Percent of isolates susceptible (row percent)a
Sex Age group (yrs) No. Ampicillin Nitrofurantoin TMP-SMXb FQsb ESCsb Gentamicin
female 13 to 20 474 51.4 86.5 66.4 87.6 88.9 94.1
21 to 30 1,824 55.6 89.5 67.2 88.6 91.4 95.0
31 to 40 1,792 55.0 89.6 64.7 88.8 89.8 95.3
41 to 50 1,268 55.9 90.1 65.9 85.4 90.2 93.7
51 to 60 1,025 54.2 87.4 63.3 83.8 89.4 93.5
61 to 70 759 55.1 88.0 60.7 78.4 87.2 91.1
71 to 80 820 54.0 84.4 57.0 74.3 84.2 90.4
> 81 738 51.6 81.1 53.6 68.7 79.6 85.7
Any of above 8,700 54.6 87.8 63.3 83.6 88.4 93.1
Male 13 to 20 36 58.6 79.3 53.6 75.9 71.4 92.9
21 to 30 65 55.8 68.8 49.1 76.9 77.4 98.0
31 to 40 102 41.6 69.1 61.4 71.3 75.3 78.3
41 to 50 98 40.2 72.4 49.4 69.0 70.1 81.4
51 to 60 160 48.5 78.0 51.9 74.3 74.1 86.7
61 to 70 187 41.6 69.8 42.8 61.2 64.3 75.2
71 to 80 229 48.1 72.1 32.6 52.9 55.6 80.5
> 81 221 35.3 54.1 28.2 42.9 46.6 71.4
Any of above 1,098 43.8 68.7 42.0 60.7 62.8 79.9
Either Any of above 9,798 53.5 85.9 61.1 81.2 85.8 91.7
ashaded cells have values < 80%, implying unsuitability for empirical therapy for cystitis; btMP-sMX, trimethoprim-sulfamethoxazole; fQs, 
fluoroquinolones (ciprofloxacin and levofloxacin); Escs, extended-spectrum cephalosoporins (ceftriaxone and cefotaxime).
Table 2 - Susceptibility of 9,798 community-source urinary isolates to six antimicrobial classes
Table 3 - Antimicrobial susceptibility of 9,798 community-source urinary isolates according to patient age and sex 
subgroup
Discussion
to guide appropriate selection of empirical antimicrobial 
therapy for acute outpatient Uti in a large Latin American city 
and to identify simple demographic and microbial predictors 
of resistance that might be more broadly generalizable, we 
analyzed susceptibility data from 9,798 consecutive positive 
urine cultures from ambulatory patients in curitiba, brazil 
(2009), in relation to host characteristics and organism. our 
findings support four main conclusions. first, resistance to 
relevant antimicrobials was problematically prevalent overall. 
second, organism mix and antimicrobial susceptibility 
differed significantly for males and females, and the male-to-
female ratio varied considerably with age, producing marked 
differences in aggregate susceptibility for different age-gender 
subgroups. third, for some subgroups, e.g., women over 60 
years  and males of any age, few or no suitable options were 
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evident, particularly for complicated infections. fourth, 
E. coli, although the single most common organism overall, 
overestimated aggregate susceptibility results, particularly for 
males and older women. these findings, which reflect today’s 
reality in a developing country setting and may foretell 
future trends in industrialized countries, demonstrate the 
importance of tailoring empirical treatment regimens to 
the patients’ demographic profile. this also indicate a 
pressing need to develop new antimicrobials, to devise 
innovative strategies for using current agents that will extend 
their utility and address existing resistance, and to closely 
monitor emerging resistance trends.
the overall susceptibility data suggested that four drug 
classes, i.e. nitrofurantoin, fQs, Escs, and gentamicin, 
should be acceptable in our community as empirical therapy, 
at least for cystitis (given the 80% susceptibility criterion 
for acceptability, notwithstanding the undesirability of 
using parenteral agents for cystitis), since they were active 
against from 81.2% (fQs) to 91.7% (gentamicin) of all urine 
isolates. However, this projection proved overly optimistic 
after stratification of the susceptibility results by age and 
gender, which identified many patient subgroups with few 
or no suitable oral antimicrobial options, particularly for 
complicated Uti. specifically, the only drugs that exhibited 
≥ 80% susceptibility among women aged 60 to 80 years were 
nitrofurantoin, Escs, and gentamicin, and among women 
older than 80, nitrofurantoin and gentamicin. in individual 
patients the suitability of even these agents might be further 
limited by patient-specific factors, such as renal dysfunction, 
hypersensitivity, concomitant nephrotoxic drugs, systemic or 
complicated infection, and desire for an all-oral regimen. thus, 
in our setting many female patients and their providers are in a 
tenuous position regarding the availability of suitable empirical 
antimicrobial therapy for community-acquired Uti.
the situation was even worse among males, for whom the 
only agent exhibiting ≥ 80% aggregate susceptibility in any 
age cohort was gentamicin, and even that drug was acceptable 
in only 5 of 8 cohorts. this poses a considerable therapeutic 
challenge with no obvious solutions. options might include 
1) administration of an initial dose of a broad-spectrum 
parenteral agent (e.g., a carbapenem or piperacillin-
tazobactam), 2) use of alternative oral agents, e.g., 
fosfomycin and amoxicillin-clavulanate (providing these 
are sufficiently active against local uropathogens, which 
requires confirmation), and 3) combination therapy, e.g., 
with amoxicillin (for enterococci) plus a Gram-negative agent. 
regardless of the empirical regimen, urine culture clearly 
should be done for all males with suspected Uti in our setting, 
to guide rational selection of an alternative regimen in case 
the initial empirical regimen proves inadequate. Additionally, 
performance of direct susceptibility testing on the initial urine 
specimen may warrant consideration, since this can provide 
susceptibility results within 24h, avoiding the delays associated 
with standardized testing of isolated colonies.11
our findings suggest that host age and sex are critical 
determinants of aggregate susceptibility prevalence, 
which are relied on by expert panels in devising empirical 
antimicrobial therapy recommendations for Uti. fortunately, 
age and gender, unlike most other resistance-associated 
epidemiological variables (e.g., prior antimicrobial exposure, 
recent health care contact, underlying complicating conditions, 
international travel, past culture results, etc.),12,13 are readily 
available at the point of care and to the clinical microbiology 
laboratory. this feature recommends their use in compiling 
stratified aggregate susceptibility results, which would allow 
informed selection of host-specific empirical treatment 
regimens for Uti, in contrast to conventional “one size fits 
all” approaches that consider only overall susceptibility data, 
and perhaps only for E. coli.1 our data indicate that clinical 
investigators and laboratories, in settings where the local 
prevalence suggests no overall resistance problem, should 
consider performing stratified analysis similar to those shown 
here, to screen for unrecognized more-resistant subgroups.
in that regard, we found that aggregate susceptibility 
data for E. coli significantly overestimated the combined 
uropathogen results by 1% to 11% per drug, and overestimated 
the non-E. coli results by even more, i.e., 3% to > 30% per drug. 
indeed, stratification by age and gender showed that E. coli 
was a suitable indicator organism for overall uropathogen 
susceptibility only among females < 60 years old. in 
contrast, for women aged over 60 and males, the overall 
E. coli susceptibility results overestimated the combined 
uropathogen susceptibility results by up to 50%. 
the encountered susceptibility results lower among males 
than females was likely due in part to men having intrinsically 
more-resistant organisms (e.g., Enterococcus, Enterobacter, 
and Pseudomonas), and to women having intrinsically more-
susceptible organisms (e.g., E. coli and S. saprophyticus). the 
observed trends toward increasing resistance with age may 
be due to older patients possibly having had more cumulative 
exposure to antimicrobials for Uti or other infections, which 
would tend to select both for more resistant species and for 
resistant variants of a given species. 
of note, despite the E. coli data underestimating the 
overall prevalence of resistance, they nonetheless indicated 
higher resistance levels than observed in previous studies of 
community-source urinary E. coli. for example, in contrast 
to our approximately 18% prevalence of fQs resistance 
in E. coli, the European Eco sEns study, which involved 
2,478 E. coli urinary isolates from 252 community health care 
centers in 17 countries (early 2000s), found approximately 
2% ciprofloxacin resistance.14,15 Likewise, a Greek study of 
1,936 E. coli uncomplicated cystitis isolates (January, 2005 to 
March, 2006) found < 5% ciprofloxacin resistance,16 whereas, as 
noted above, a London study from 2005-2006 showed 9.3% fQs 
resistance among E. coli from the local community (including 
some hospitalized patients). Whether our markedly higher 
resistance prevalence reflects differences in geography, time 
period, patient selection, or other factors is unknown.
notably, our E. coli resistance results were actually 
comparable to those documented previously among 
hospitalized patients, including in regions known for fQ 
resistance. for example, the spanish EArss study, with 7,098 
invasive E. coli isolates from 32 spanish hospitals (2001-2003), 
reported resistance prevalence values for ciprofloxacin (19.3%) 
and tMP/sMX (32.6%)17 similar to those observed among our 
outpatient E. coli isolates (17.8% and 34.3%, respectively). 
Likewise, the multi-center Latin American sEntrY study of 
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1,961 E. coli urinary isolates from hospitalized patients (1997 
and 2000) found fQ resistance prevalence values similar to 
ours (17.5-18.9%).9 this suggests that over the past decade 
in our region of Latin America the prevalence of fQs resistance 
among outpatient E. coli isolates has risen to levels previously 
associated with hospital isolates. 
Limitations of the study warrant attention. first, 
potentially relevant variables such as clinical manifestations, 
severity of illness, comorbid or predisposing conditions, Uti 
history, and prior antibiotic exposure were not analyzed. 
second, as in most surveillance studies, selection bias 
is possible regarding which patients had urine cultures 
performed. Accordingly, our findings might represent 
a “worst-case” scenario, if cultures were biased toward 
patients in whom resistance was anticipated based 
on persistent or recurrent infection, prior antimicrobial use, 
complicating conditions, etc. third, the clinical significance 
for Uti therapy of in vitro resistance is uncertain for most 
drug classes. Although tMP-sMX resistance clearly predicts 
treatment failure in cystitis or pyelonephritis,18 for other 
drugs this remains poorly defined. fourth, we analyzed ente-
rococcal susceptibility to gentamicin using synergy-based 
criteria, which likely overestimated the actual suitability 
of gentamicin for empirical therapy. this would tend to 
strengthen our conclusion regarding limited treatment 
options, especially for males, among whom the enterococcal 
infections were concentrated. As such, our conclusions 
may actually understate the gravity of the situation. study 
strengths include the large and recent study population; 
inclusion of multiple widely distributed clinics within the 
study community, which provided a quasi-population-based 
analysis; and inclusion of all qualifying urine cultures, which 
permitted analysis by age and gender and made the results 
relevant to the entire community of patients with Uti. 
in conclusion, this large surveillance study identified serious 
problems with antimicrobial resistance among recent (2009) 
community-source urinary organisms in a large southern 
brazilian city. stratification by gender and age identified a 
dearth of suitable empirical treatment options for women 
over 60 years and males of any age, and E. coli proved to be an 
unsuitable indicator organism for uropathogen susceptibility 
except among females ≤ 60 years old. our findings challenge 
the notion that no guideline-suggested antimicrobial regimen, 
especially based on aggregate E. coli susceptibility data, can fit 
all. since gender and age are readily available demographics, 
we propose that age and gender-stratified surveillance studies 
that include all uropathogens (not just E. coli) should be done in 
each setting and, ideally, repeated at intervals, since resistance 
is a moving target. Additionally, development of new 
antimicrobials, prudent and creative use of available agents, 
and improved methods for prediction and rapid detection of 
resistance are clearly needed.
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